Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC)

Related Keywords

Israel ,Dana Farber Cancer Institute ,Massachusetts ,United States ,Columbus ,Ohio ,Canada ,American ,Dsenthil Damodaran ,Simon Jenkins ,Paul Plourde ,Elizabeth Attias ,David Portman ,Barry Komm ,Miriam Portman ,Harvard Medical School ,Parke Davis Pharmaceuticals ,University Of Miami ,Astrazeneca ,Sermonix Pharmaceuticals Inc ,Phd Md Anderson Cancer Center ,Hospital Cancer Center ,Phd Harvard Medical School ,Cornell University ,American Society Of Clinical Oncology ,Md Anderson Cancer Center ,Pharmaceuticals Inc ,Cancer Center ,Seth Wander ,Massachusetts General Hospital ,Evaluating Lasofoxifene ,Investigational Cancer Therapeutics ,American Society ,Clinical Oncology ,American Board ,Internal Medicine ,Cell Biology ,Cancer Biology ,Massachusetts General Hospital Cancer ,Conquer Cancer ,Clinical Oncology Young Investigator ,Anthony Wild ,